AKT1 and cholangiocarcinoma: For example, miR-10b-3p upregulation was shown to enhance HCC progression via suppressing CMTM5 expression [34], while miR-885-5p was able to target GALNT3 and to thereby inhibit PI3K/AKT/MMP signaling to disrupt intrahepatic cholangiocarcinoma metastasis [35].